STERIS plc $STE Shares Sold by ANTIPODES PARTNERS Ltd

ANTIPODES PARTNERS Ltd reduced its stake in STERIS plc (NYSE:STE) by 51.2% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 260 shares of the medical equipment provider’s stock after selling 273 shares during the quarter. ANTIPODES PARTNERS Ltd’s holdings in STERIS were worth $62,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. increased its stake in STERIS by 416.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 104 shares during the period. Zions Bancorporation National Association UT purchased a new stake in STERIS during the 1st quarter worth approximately $37,000. Costello Asset Management INC purchased a new stake in STERIS during the 1st quarter worth approximately $45,000. Wayfinding Financial LLC purchased a new stake in STERIS during the 1st quarter worth approximately $46,000. Finally, Atticus Wealth Management LLC purchased a new stake in STERIS during the 2nd quarter worth approximately $68,000. 94.69% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Cynthia L. Feldmann sold 3,495 shares of the company’s stock in a transaction on Monday, August 11th. The shares were sold at an average price of $241.56, for a total value of $844,252.20. Following the completion of the transaction, the director owned 705 shares in the company, valued at approximately $170,299.80. This represents a 83.21% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO Karen L. Burton sold 7,900 shares of the company’s stock in a transaction on Monday, August 11th. The shares were sold at an average price of $241.73, for a total transaction of $1,909,667.00. Following the completion of the transaction, the chief accounting officer owned 5,994 shares of the company’s stock, valued at approximately $1,448,929.62. The trade was a 56.86% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 18,868 shares of company stock worth $4,585,389. 1.07% of the stock is currently owned by company insiders.

STERIS Trading Down 0.2%

Shares of NYSE:STE opened at $235.75 on Friday. STERIS plc has a 52 week low of $200.98 and a 52 week high of $253.00. The company’s 50 day moving average is $243.79 and its two-hundred day moving average is $238.03. The company has a current ratio of 2.22, a quick ratio of 1.53 and a debt-to-equity ratio of 0.27. The company has a market cap of $23.22 billion, a PE ratio of 36.10 and a beta of 1.01.

STERIS (NYSE:STE) last announced its quarterly earnings data on Wednesday, August 6th. The medical equipment provider reported $2.34 EPS for the quarter, beating analysts’ consensus estimates of $2.32 by $0.02. STERIS had a net margin of 11.61% and a return on equity of 14.17%. The company had revenue of $1.40 billion for the quarter, compared to the consensus estimate of $1.36 billion. During the same period in the prior year, the firm posted $2.03 EPS. The company’s quarterly revenue was up 8.8% compared to the same quarter last year. Equities analysts predict that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 18th. Stockholders of record on Tuesday, November 18th will be issued a $0.63 dividend. The ex-dividend date is Tuesday, November 18th. This represents a $2.52 annualized dividend and a dividend yield of 1.1%. STERIS’s dividend payout ratio is presently 38.59%.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Morgan Stanley upped their target price on shares of STERIS from $276.00 to $295.00 and gave the stock an “overweight” rating in a research note on Friday, August 8th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of STERIS in a research note on Tuesday, October 14th. Wall Street Zen raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 14th. Finally, KeyCorp increased their price objective on shares of STERIS from $277.00 to $288.00 and gave the company an “overweight” rating in a research report on Tuesday, July 22nd. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $273.50.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.